ArticleOncotarget2018

Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.

Yasutaka Tono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.